| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Extracorporeal Membrane Oxygenation | 13 | 2023 | 581 | 3.850 |
Why?
|
| Heparin | 16 | 2023 | 360 | 2.870 |
Why?
|
| Thrombosis | 12 | 2023 | 781 | 2.380 |
Why?
|
| Anticoagulants | 17 | 2023 | 787 | 2.360 |
Why?
|
| Hemorrhage | 11 | 2022 | 712 | 2.280 |
Why?
|
| Blood Coagulation | 12 | 2023 | 185 | 2.180 |
Why?
|
| Thrombelastography | 7 | 2021 | 79 | 1.920 |
Why?
|
| Partial Thromboplastin Time | 7 | 2021 | 55 | 1.910 |
Why?
|
| Antithrombins | 6 | 2022 | 74 | 1.840 |
Why?
|
| Blood Coagulation Disorders | 7 | 2021 | 120 | 1.640 |
Why?
|
| Hemostasis | 7 | 2022 | 109 | 1.580 |
Why?
|
| Heart-Assist Devices | 10 | 2023 | 1171 | 1.520 |
Why?
|
| Hirudins | 5 | 2024 | 65 | 1.480 |
Why?
|
| Blood Coagulation Tests | 9 | 2021 | 87 | 1.320 |
Why?
|
| Hemostatics | 4 | 2021 | 88 | 1.310 |
Why?
|
| von Willebrand Diseases | 4 | 2019 | 61 | 1.250 |
Why?
|
| Drug Monitoring | 5 | 2020 | 333 | 1.220 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2020 | 422 | 1.200 |
Why?
|
| Factor VIII | 4 | 2020 | 75 | 1.110 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 4 | 2015 | 110 | 1.080 |
Why?
|
| Erythrocyte Transfusion | 6 | 2020 | 212 | 1.060 |
Why?
|
| ADAM Proteins | 3 | 2015 | 134 | 1.040 |
Why?
|
| Thrombophilia | 3 | 2022 | 56 | 0.980 |
Why?
|
| Peptide Fragments | 6 | 2024 | 1271 | 0.960 |
Why?
|
| Citrates | 1 | 2024 | 39 | 0.950 |
Why?
|
| Citric Acid | 1 | 2024 | 54 | 0.930 |
Why?
|
| Factor Xa | 3 | 2017 | 26 | 0.910 |
Why?
|
| Plasma | 3 | 2020 | 158 | 0.910 |
Why?
|
| Factor V | 3 | 2022 | 20 | 0.830 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2023 | 1237 | 0.790 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2021 | 29 | 0.780 |
Why?
|
| Blood Transfusion | 3 | 2019 | 583 | 0.740 |
Why?
|
| Fetal Blood | 3 | 2016 | 482 | 0.740 |
Why?
|
| Placenta Accreta | 5 | 2019 | 122 | 0.690 |
Why?
|
| Hemoglobins | 3 | 2015 | 477 | 0.630 |
Why?
|
| Menorrhagia | 3 | 2013 | 66 | 0.630 |
Why?
|
| Child | 38 | 2023 | 29154 | 0.620 |
Why?
|
| Whole Blood Coagulation Time | 3 | 2014 | 16 | 0.610 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 3 | 2014 | 68 | 0.610 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 527 | 0.590 |
Why?
|
| Blood Platelets | 7 | 2020 | 731 | 0.580 |
Why?
|
| Vitamin K Deficiency | 1 | 2016 | 4 | 0.570 |
Why?
|
| Infant, Newborn | 15 | 2022 | 8223 | 0.560 |
Why?
|
| International Normalized Ratio | 1 | 2016 | 48 | 0.560 |
Why?
|
| Vitamin K | 1 | 2016 | 54 | 0.550 |
Why?
|
| Warfarin | 3 | 2012 | 152 | 0.550 |
Why?
|
| Humans | 86 | 2024 | 261506 | 0.540 |
Why?
|
| Recombinant Proteins | 5 | 2023 | 2927 | 0.520 |
Why?
|
| Heart Defects, Congenital | 3 | 2023 | 1697 | 0.510 |
Why?
|
| Protein Precursors | 1 | 2016 | 240 | 0.510 |
Why?
|
| alpha-2-Antiplasmin | 1 | 2014 | 4 | 0.500 |
Why?
|
| Zika Virus Infection | 1 | 2017 | 166 | 0.500 |
Why?
|
| Fibrinolysin | 1 | 2014 | 33 | 0.490 |
Why?
|
| Infusions, Parenteral | 1 | 2014 | 191 | 0.490 |
Why?
|
| Fibrinogen | 5 | 2021 | 205 | 0.490 |
Why?
|
| Health Information Systems | 1 | 2014 | 34 | 0.480 |
Why?
|
| Factor Xa Inhibitors | 1 | 2014 | 70 | 0.480 |
Why?
|
| Plasma Exchange | 3 | 2018 | 117 | 0.460 |
Why?
|
| Bilirubin | 1 | 2014 | 221 | 0.460 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2013 | 24 | 0.460 |
Why?
|
| Blood Banks | 2 | 2015 | 33 | 0.450 |
Why?
|
| beta-Alanine | 1 | 2012 | 8 | 0.440 |
Why?
|
| Platelet Function Tests | 5 | 2015 | 50 | 0.440 |
Why?
|
| Infant | 20 | 2019 | 13310 | 0.430 |
Why?
|
| Riots | 1 | 2012 | 6 | 0.430 |
Why?
|
| Blood Safety | 1 | 2012 | 10 | 0.430 |
Why?
|
| Peptide Hydrolases | 1 | 2014 | 256 | 0.430 |
Why?
|
| Child, Preschool | 25 | 2022 | 16273 | 0.430 |
Why?
|
| Blood Platelet Disorders | 1 | 2012 | 37 | 0.420 |
Why?
|
| Hysterectomy | 5 | 2019 | 611 | 0.420 |
Why?
|
| Thrombocytopenia | 2 | 2014 | 846 | 0.420 |
Why?
|
| Blood Loss, Surgical | 5 | 2019 | 309 | 0.390 |
Why?
|
| Blood Coagulation Factor Inhibitors | 1 | 2010 | 3 | 0.380 |
Why?
|
| Retrospective Studies | 28 | 2023 | 37905 | 0.370 |
Why?
|
| Female | 48 | 2022 | 141928 | 0.360 |
Why?
|
| Thrombin | 1 | 2010 | 99 | 0.360 |
Why?
|
| Disseminated Intravascular Coagulation | 3 | 2022 | 106 | 0.360 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2012 | 598 | 0.340 |
Why?
|
| Benzimidazoles | 1 | 2012 | 428 | 0.340 |
Why?
|
| Prothrombin Time | 4 | 2016 | 44 | 0.330 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 399 | 0.320 |
Why?
|
| Platelet Transfusion | 3 | 2019 | 156 | 0.310 |
Why?
|
| Blood Component Removal | 2 | 2012 | 121 | 0.310 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2007 | 7 | 0.310 |
Why?
|
| Enoxaparin | 2 | 2017 | 66 | 0.300 |
Why?
|
| Biomarkers | 2 | 2016 | 5047 | 0.300 |
Why?
|
| Databases, Factual | 1 | 2014 | 2218 | 0.300 |
Why?
|
| Adolescent | 23 | 2023 | 31252 | 0.300 |
Why?
|
| Serologic Tests | 1 | 2007 | 137 | 0.290 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2007 | 203 | 0.280 |
Why?
|
| Stroke | 3 | 2023 | 1144 | 0.280 |
Why?
|
| Fibrinolytic Agents | 2 | 2020 | 324 | 0.280 |
Why?
|
| Antithrombin III | 2 | 2017 | 28 | 0.280 |
Why?
|
| Heart Transplantation | 2 | 2023 | 908 | 0.280 |
Why?
|
| Anemia, Sickle Cell | 2 | 2011 | 339 | 0.280 |
Why?
|
| Preoperative Care | 1 | 2012 | 1529 | 0.270 |
Why?
|
| Prothrombin | 2 | 2016 | 36 | 0.270 |
Why?
|
| Male | 33 | 2020 | 123000 | 0.260 |
Why?
|
| Heart Failure | 3 | 2023 | 2516 | 0.250 |
Why?
|
| Blood Group Incompatibility | 3 | 2018 | 34 | 0.250 |
Why?
|
| Hypersensitivity | 2 | 2021 | 216 | 0.250 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2009 | 444 | 0.250 |
Why?
|
| Pregnancy | 9 | 2022 | 7573 | 0.250 |
Why?
|
| Aspirin | 2 | 2008 | 455 | 0.240 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2003 | 11 | 0.240 |
Why?
|
| Protein S | 2 | 2016 | 11 | 0.240 |
Why?
|
| Protein C | 2 | 2016 | 32 | 0.240 |
Why?
|
| Activated Protein C Resistance | 1 | 2022 | 3 | 0.230 |
Why?
|
| Immunologic Factors | 1 | 2007 | 649 | 0.230 |
Why?
|
| Egypt | 2 | 2013 | 42 | 0.220 |
Why?
|
| Cerebrovascular Disorders | 1 | 2003 | 142 | 0.220 |
Why?
|
| ABO Blood-Group System | 2 | 2018 | 127 | 0.220 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 4892 | 0.220 |
Why?
|
| Protein C Deficiency | 1 | 2022 | 12 | 0.220 |
Why?
|
| Fibrinolysis | 2 | 2014 | 63 | 0.220 |
Why?
|
| Blood Grouping and Crossmatching | 2 | 2013 | 37 | 0.210 |
Why?
|
| Prospective Studies | 7 | 2021 | 12873 | 0.210 |
Why?
|
| Age Factors | 6 | 2018 | 5377 | 0.210 |
Why?
|
| Blood Chemical Analysis | 2 | 2014 | 118 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 2403 | 0.210 |
Why?
|
| Isoantibodies | 2 | 2013 | 115 | 0.200 |
Why?
|
| Afibrinogenemia | 1 | 2021 | 10 | 0.200 |
Why?
|
| Cesarean Section | 4 | 2019 | 367 | 0.200 |
Why?
|
| Postpartum Hemorrhage | 2 | 2019 | 81 | 0.200 |
Why?
|
| Pregnancy Trimesters | 1 | 2021 | 36 | 0.190 |
Why?
|
| Adult | 17 | 2023 | 77950 | 0.190 |
Why?
|
| Heparitin Sulfate | 1 | 2020 | 35 | 0.190 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2020 | 25 | 0.190 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 128 | 0.180 |
Why?
|
| Coagulants | 1 | 2019 | 8 | 0.180 |
Why?
|
| Anaphylaxis | 1 | 2021 | 119 | 0.180 |
Why?
|
| Referral and Consultation | 1 | 2005 | 899 | 0.170 |
Why?
|
| Time Factors | 6 | 2022 | 12926 | 0.170 |
Why?
|
| Liver Failure | 1 | 2020 | 140 | 0.170 |
Why?
|
| Young Adult | 8 | 2023 | 21445 | 0.170 |
Why?
|
| Hypocalcemia | 1 | 2019 | 59 | 0.170 |
Why?
|
| Factor IX | 3 | 2023 | 30 | 0.170 |
Why?
|
| Blood Coagulation Factors | 2 | 2023 | 59 | 0.160 |
Why?
|
| von Willebrand Factor | 3 | 2018 | 335 | 0.160 |
Why?
|
| Materials Testing | 1 | 2018 | 116 | 0.160 |
Why?
|
| Treatment Outcome | 9 | 2023 | 32848 | 0.160 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2019 | 441 | 0.160 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 144 | 0.150 |
Why?
|
| Surface Properties | 1 | 2018 | 180 | 0.150 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2018 | 70 | 0.150 |
Why?
|
| Quality Assurance, Health Care | 2 | 2012 | 585 | 0.140 |
Why?
|
| ADAMTS13 Protein | 2 | 2014 | 92 | 0.140 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2016 | 19 | 0.140 |
Why?
|
| Thromboembolism | 1 | 2017 | 155 | 0.140 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 263 | 0.140 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 4314 | 0.140 |
Why?
|
| Syndrome | 1 | 2019 | 1351 | 0.140 |
Why?
|
| Clinical Protocols | 2 | 2018 | 467 | 0.140 |
Why?
|
| Pediatrics | 1 | 2005 | 1141 | 0.140 |
Why?
|
| Inventories, Hospital | 1 | 2015 | 1 | 0.140 |
Why?
|
| Staphylococcus aureus | 2 | 2012 | 548 | 0.130 |
Why?
|
| Platelet Adhesiveness | 1 | 2015 | 57 | 0.130 |
Why?
|
| Blood Donors | 2 | 2015 | 164 | 0.130 |
Why?
|
| Term Birth | 1 | 2015 | 30 | 0.130 |
Why?
|
| Blood Preservation | 1 | 2015 | 54 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 280 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 602 | 0.130 |
Why?
|
| Placenta, Retained | 1 | 2014 | 13 | 0.130 |
Why?
|
| Pipecolic Acids | 1 | 2014 | 13 | 0.130 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2015 | 46 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2018 | 603 | 0.130 |
Why?
|
| Thromboxane B2 | 1 | 2014 | 27 | 0.120 |
Why?
|
| Drug Resistance | 2 | 2008 | 587 | 0.120 |
Why?
|
| Liver Transplantation | 2 | 2018 | 1112 | 0.120 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 187 | 0.120 |
Why?
|
| Models, Biological | 3 | 2017 | 3254 | 0.120 |
Why?
|
| Leukocyte Transfusion | 1 | 2014 | 43 | 0.120 |
Why?
|
| Staphylococcal Infections | 2 | 2012 | 672 | 0.120 |
Why?
|
| Nutritional Status | 1 | 2016 | 337 | 0.120 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2014 | 91 | 0.120 |
Why?
|
| Cattle | 2 | 2018 | 783 | 0.120 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2013 | 15 | 0.120 |
Why?
|
| Granulocytes | 1 | 2014 | 224 | 0.110 |
Why?
|
| Cardiomyopathies | 1 | 2018 | 610 | 0.110 |
Why?
|
| Food-Drug Interactions | 1 | 2012 | 22 | 0.110 |
Why?
|
| Dabigatran | 1 | 2012 | 27 | 0.110 |
Why?
|
| Drug Contamination | 1 | 2012 | 52 | 0.110 |
Why?
|
| Subcutaneous Tissue | 1 | 2012 | 62 | 0.110 |
Why?
|
| Hospitals, Urban | 1 | 2012 | 87 | 0.100 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 334 | 0.100 |
Why?
|
| Seroepidemiologic Studies | 1 | 2012 | 129 | 0.100 |
Why?
|
| Syphilis | 1 | 2012 | 61 | 0.100 |
Why?
|
| Heparin Lyase | 1 | 2010 | 3 | 0.100 |
Why?
|
| Laboratories | 1 | 2012 | 145 | 0.100 |
Why?
|
| Polysaccharides | 1 | 2012 | 197 | 0.100 |
Why?
|
| Arginine | 1 | 2014 | 500 | 0.100 |
Why?
|
| Meconium Aspiration Syndrome | 1 | 2010 | 15 | 0.100 |
Why?
|
| Hemodynamics | 1 | 2015 | 935 | 0.100 |
Why?
|
| Pathology, Clinical | 1 | 2012 | 152 | 0.100 |
Why?
|
| Reference Values | 2 | 2015 | 1099 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2015 | 785 | 0.100 |
Why?
|
| Coinfection | 1 | 2012 | 189 | 0.100 |
Why?
|
| Necrosis | 1 | 2012 | 580 | 0.100 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2012 | 242 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 4938 | 0.090 |
Why?
|
| Postoperative Complications | 3 | 2023 | 5542 | 0.090 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2010 | 121 | 0.090 |
Why?
|
| Outpatients | 2 | 2022 | 462 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2012 | 241 | 0.090 |
Why?
|
| Intraoperative Complications | 1 | 2012 | 301 | 0.090 |
Why?
|
| Factor XII | 1 | 2009 | 4 | 0.090 |
Why?
|
| Hemophilia B | 1 | 2009 | 14 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 787 | 0.090 |
Why?
|
| Neutropenia | 1 | 2014 | 968 | 0.090 |
Why?
|
| Skin Diseases | 1 | 2012 | 349 | 0.090 |
Why?
|
| Hepatitis B | 1 | 2012 | 258 | 0.090 |
Why?
|
| Polycythemia | 1 | 2009 | 49 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2011 | 829 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2011 | 223 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2018 | 6550 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2012 | 1544 | 0.080 |
Why?
|
| Artifacts | 1 | 2010 | 532 | 0.080 |
Why?
|
| Incidence | 2 | 2015 | 5673 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2011 | 576 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 3203 | 0.070 |
Why?
|
| Cardiac Catheterization | 1 | 2011 | 687 | 0.070 |
Why?
|
| Hepatitis C | 1 | 2012 | 524 | 0.070 |
Why?
|
| Wilms Tumor | 1 | 2009 | 292 | 0.070 |
Why?
|
| Pathology | 1 | 2007 | 101 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 502 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 1375 | 0.070 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2005 | 22 | 0.070 |
Why?
|
| Erythrocyte Count | 1 | 2005 | 38 | 0.070 |
Why?
|
| Erythrocyte Indices | 1 | 2005 | 24 | 0.070 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2005 | 19 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2010 | 462 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2014 | 1823 | 0.070 |
Why?
|
| Rodenticides | 1 | 2004 | 2 | 0.070 |
Why?
|
| Anemia, Hemolytic | 1 | 2005 | 53 | 0.060 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 1303 | 0.060 |
Why?
|
| Influenza, Human | 1 | 2012 | 925 | 0.060 |
Why?
|
| Sepsis | 1 | 2010 | 652 | 0.060 |
Why?
|
| Genotype | 1 | 2013 | 4109 | 0.060 |
Why?
|
| Mycophenolic Acid | 1 | 2005 | 148 | 0.060 |
Why?
|
| Hematuria | 1 | 2004 | 85 | 0.060 |
Why?
|
| Factor VIIa | 1 | 2023 | 31 | 0.060 |
Why?
|
| Risk Factors | 5 | 2019 | 17523 | 0.060 |
Why?
|
| Intracranial Hemorrhages | 1 | 2004 | 121 | 0.060 |
Why?
|
| Ischemic Attack, Transient | 1 | 2003 | 55 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2009 | 1694 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 6009 | 0.060 |
Why?
|
| Osteomyelitis | 1 | 2006 | 236 | 0.060 |
Why?
|
| Hospitals, Pediatric | 2 | 2019 | 773 | 0.050 |
Why?
|
| Patient Care Team | 2 | 2019 | 795 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 384 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2014 | 9244 | 0.050 |
Why?
|
| Platelet Aggregation | 2 | 2013 | 257 | 0.050 |
Why?
|
| Fibrin | 1 | 2020 | 82 | 0.050 |
Why?
|
| Body Weights and Measures | 1 | 2019 | 52 | 0.050 |
Why?
|
| Body Weight | 2 | 2017 | 1293 | 0.040 |
Why?
|
| Half-Life | 1 | 2019 | 259 | 0.040 |
Why?
|
| HIV Infections | 1 | 2012 | 2134 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2015 | 1487 | 0.040 |
Why?
|
| Blood Component Transfusion | 1 | 2019 | 89 | 0.040 |
Why?
|
| Animals | 4 | 2018 | 59536 | 0.040 |
Why?
|
| Placenta Previa | 1 | 2019 | 61 | 0.040 |
Why?
|
| Obesity | 1 | 2011 | 2884 | 0.040 |
Why?
|
| Middle Aged | 5 | 2023 | 86204 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2003 | 2316 | 0.040 |
Why?
|
| Inpatients | 1 | 2003 | 678 | 0.040 |
Why?
|
| Hemolysis | 1 | 2018 | 127 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2018 | 116 | 0.040 |
Why?
|
| Biological Variation, Population | 1 | 2017 | 22 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 403 | 0.040 |
Why?
|
| Isotonic Solutions | 1 | 2017 | 46 | 0.040 |
Why?
|
| Body Composition | 1 | 2019 | 595 | 0.040 |
Why?
|
| Device Removal | 1 | 2018 | 337 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 1204 | 0.040 |
Why?
|
| Benchmarking | 1 | 2018 | 273 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2019 | 6100 | 0.030 |
Why?
|
| Integrin alpha2 | 1 | 2015 | 11 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2018 | 749 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 4320 | 0.030 |
Why?
|
| Erythrocyte Aging | 1 | 2015 | 14 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 703 | 0.030 |
Why?
|
| Birth Weight | 1 | 2017 | 374 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 1382 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 4971 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2019 | 1529 | 0.030 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2013 | 16 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2019 | 830 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2018 | 834 | 0.030 |
Why?
|
| Gestational Age | 1 | 2017 | 1069 | 0.030 |
Why?
|
| Immune System | 1 | 2015 | 279 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 244 | 0.030 |
Why?
|
| Autopsy | 1 | 2013 | 173 | 0.030 |
Why?
|
| Antifibrinolytic Agents | 1 | 2013 | 68 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 2315 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2014 | 684 | 0.030 |
Why?
|
| Platelet Count | 1 | 2013 | 490 | 0.030 |
Why?
|
| Prognosis | 2 | 2021 | 21713 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 621 | 0.030 |
Why?
|
| Antibodies | 1 | 2015 | 838 | 0.030 |
Why?
|
| Medical Audit | 1 | 2012 | 188 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 700 | 0.030 |
Why?
|
| Algorithms | 2 | 2013 | 3890 | 0.020 |
Why?
|
| Glomerular Basement Membrane | 1 | 2011 | 22 | 0.020 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2011 | 26 | 0.020 |
Why?
|
| Glomerulonephritis | 1 | 2011 | 109 | 0.020 |
Why?
|
| Software | 1 | 2017 | 1321 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 1183 | 0.020 |
Why?
|
| Medical Records | 1 | 2011 | 415 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2011 | 263 | 0.020 |
Why?
|
| Epidemiologic Measurements | 1 | 2008 | 4 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 2843 | 0.020 |
Why?
|
| Acute Disease | 1 | 2014 | 2422 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2013 | 717 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 2083 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2012 | 451 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 475 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 6311 | 0.020 |
Why?
|
| Factor XI | 1 | 2007 | 2 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 1900 | 0.020 |
Why?
|
| Critical Illness | 1 | 2012 | 714 | 0.020 |
Why?
|
| Chemistry, Clinical | 1 | 2007 | 18 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 2238 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 509 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 2049 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 147 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2011 | 620 | 0.020 |
Why?
|
| Graft vs Host Reaction | 1 | 2005 | 59 | 0.020 |
Why?
|
| Quality Control | 1 | 2007 | 457 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 2638 | 0.010 |
Why?
|
| Community-Acquired Infections | 1 | 2006 | 285 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2011 | 2203 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 14889 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 329 | 0.010 |
Why?
|
| United States | 2 | 2011 | 15433 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2009 | 1616 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 15179 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2005 | 769 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 3260 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2012 | 6869 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 6942 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 7551 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 34495 | 0.000 |
Why?
|